<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39419771</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Dexamethasone Dose for COVID-19 in a Large U.S. Hospital Network From April 2020 to May 2023.</ArticleTitle><Pagination><StartPage>e70018</StartPage><MedlinePgn>e70018</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70018</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">While potential harm from high doses of systemic dexamethasone for clinical management of COVID-19 is an important concern, little is known about real world dexamethasone dosing in patients hospitalized with COVID-19 in the United States.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Descriptive study to assess dexamethasone daily dose in adults with COVID-19 in a large US hospital network, overall and by respiratory support requirements, extracted using semi- structured nursing notes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 332 430 hospitalizations with a COVID-19 diagnosis, 201 637 (60.7%) hospitalizations included dexamethasone administration. The mean age of recipients was 63 years, 53.0% were male, and 64.5% White. Median time from admission to dexamethasone administration was 0 day (interquartile range [IQR], 0-1 days) and median duration of use was 5 (IQR, 3-9) days. Almost 80% of hospitalizations received standard daily doses (≤ 6 mg daily), 12.7% moderately high daily doses (&gt; 6- ≤ 10 mg daily), and 8.1% high (&gt; 10- ≤ 20 mg daily) or very high daily dose (&gt; 20 mg daily). Over 20% of COVID-19 hospitalizations requiring no oxygen or simple oxygen received high doses of systemic dexamethasone.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Given the findings from the UK RECOVERY trial, and the general uncertainty around safety of higher dexamethasone doses in those requiring more intense respiratory support, standard daily dexamethasone doses of 6 mg or less for hospitalized COVID-19 requiring supplemental oxygen are recommended.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Marie C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-3231-9951</Identifier><AffiliationInfo><Affiliation>Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosgrove</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Vilar</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1272-1502</Identifier><AffiliationInfo><Affiliation>Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Candace</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eworuke</LastName><ForeName>Efe</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology and Drug Safety Team, Real World Solutions, IQVIA, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>HCA Healthcare, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guy</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>HCA Healthcare, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poland</LastName><ForeName>Russell E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HCA Healthcare, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sands</LastName><ForeName>Kenneth E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HCA Healthcare, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dal Pan</LastName><ForeName>Gerald J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">electronic medical records</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39419771</ArticleId><ArticleId IdType="doi">10.1002/pds.70018</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Recovery Collaborative Group, P. Horby, W. S. Lim, et al., “Dexamethasone in Hospitalized Patients With Covid‐19,” New England Journal of Medicine 384, no. 8 (2021): 693–704.</Citation></Reference><Reference><Citation>National Institutes of Health, “Therapeutic Management of Hospitalized Adults With COVID‐19,” accessed December 21, 2023, https://www.covid19treatmentguidelines.nih.gov/management/clinical‐management‐of‐adults/hospitalized‐adults‐‐therapeutic‐management/.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group, “RECOVERY Trial to Investigate Whether Higher Doses of Dexamethasone Deliver Greater Benefit for Patients with Severe COVID‐19,” accessed January 19, 2024, https://www.recoverytrial.net/news/recovery‐trial‐to‐investigate‐whether‐higher‐doses‐of‐dexamethasone‐deliver‐greater‐benefit‐for‐patients‐with‐severe‐covid‐19.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group, “Recruitment to higher Dose Corticosteroids Closed for Patients With Hypoxia on No Oxygen Or Receiving Simple Oxygen,” 2023, https://www.recoverytrial.net/news/recruitment‐to‐higher‐dose‐corticosteroids‐closed‐for‐patients‐with‐hypoxia‐on‐no‐oxygen‐or‐receiving‐simple‐oxygen.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group, “Higher Dose Corticosteroids in Patients Admitted to Hospital With COVID‐19 Who Are Hypoxic But Not Requiring Ventilatory Support (RECOVERY): A Randomised, Controlled, Open‐Label, Platform Trial,” Lancet 401, no. 10387 (2023): 1499–1507.</Citation></Reference><Reference><Citation>K. J. N. S. M. Rosati and B. J. Evans, “Sentinel Initiative Principles and Policies: HIPAA and Common Rule Compliance in the Sentinel Initiative,” 2018, https://www.sentinelinitiative.org/sites/default/files/communications/publications‐presentations/HIPAA‐Common‐Rule‐Compliance‐in‐Sentinel‐Initiative.pdf.</Citation></Reference><Reference><Citation>F. P. Havers, H. Pham, C. A. Taylor, et al., “COVID‐19‐Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022,” JAMA Internal Medicine 182, no. 10 (2022): 1071–1081.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>